Skip to main content

Search

Study Title Study Sponsor Status Study Drug Trial Phase Study Protocol Number Site
The Effectiveness of Convalescent Plasma Transfusion in Preventing Clinical Deterioration and Critical Care Admission in COVID 19 Patients at a Primary Corona Centre in Riyadh, Saudi Arabia PMBAH Ongoing Convalescent Plasma 2 20-252C Prince Mohammad bin Abdulaziz hospital (Riyadh)
The Effectiveness of Convalescent Plasma for the Treatment of Severe COVID-19 Cases in Intensive Care Unit King Faisal Specialist Hospital and Research Centre Ongoing Convalescent Plasma 3 IRB 2020-19-V2 KFSH&RC-J
The effect of Zamzam water on the immunity of healthy university students in the eastern province of Saudi Arabia PI initiated Completed Zamzam water 2 IRB-2020-01-393 Imam Abdulrahman Al Faisal Hospital (Riyadh)
The Effect of Rectal Progesterone on the Latency period as well as Maternal and Prenatal Outcome in PPROM Between 24-33+6 Weeks Umm Al Qura University Ongoing Progesterone 3 ISRCTN65694106 UQU
The effect of cinnamon supplementation on ovulation induction in women with polycystic ovary syndrome, Jeddah 2018: Randomized Double-Blind Placebo-controlled trial Dr. Wael Alzhrani (PI-initiated) Ongoing Cinnamon 3 100-18 KAUH-J
The effect of (Oligonol) and (Oligonol + metformin) on the components of Metabolic Syndrome in obese individuals- A randomized, double-blind, factorial clinical trial. Amino Up Chemical Co., Ltd. Ongoing Oligonol 3 SDRG- Amino Up 1 KFMRC-J
Superiority of Insulin Glargine Lantus vs. NPH: Treat to Normoglycemia Concept.Effect of Insulin Glargine in Comparison to Insulin NPH in Insulin-nave People With Type 2 Diabetes Mellitus Treated With at Least One OAD and Not Adequately Controlled Sanofi Completed Lantus® 3 LANTU_C_02762 KFUH
"Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy" Inovio Pharmaceuticals, Inc. Completed NO-4700 + CELLECTRA™ 2000 (device) 2 MERS-201 KSMC
Study of Aflibercept in Uveitic Macular EDema (SAUD study) King Khalid Specialist Hospital Rejected Aflibercept 3b 18176 KKESH
"Study H9X-MC-GBGC is a Phase 3, randomized, double-blind, placebo-controlled trial with an open-label extension that investigates the effect of the addition of dulaglutide (0.75 and 1.5 mg/week) or placebo weekly to metformin and/or basal insulin on change from baseline in hemoglobin A1c at 26 weeks in children and adolescents with type 2 diabetes mellitus" Eli Lilly Ongoing Dulaglutide 0.75 /1.5 mg 3 H9X-MC-GBGC KKUH
View 141 - 150 From 712